Table 3.
Comparison of selected hemodynamic results at baseline (day 0) and final evaluation (day 15) in dogs treated with sildenafil or tadalafil in which the echocardiographic parameter was measured at both time points using a two-way repeated measures analysis of variance.
| Baseline | Final | p-value | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Variable | n | Sildenafil | n | Tadalafil | Sildenafil | Tadalafil | A | B | C |
| Peak TRFV (m/s) | 5 | 4.09 (0.58) | 8 | 4.13 (0.52) | 3.94 (0.67) | 3.57 (0.35) | 0.51 | 0.056 | 0.24 |
| Estimated sPAP (mmHg) | 5 | 74.00 (19.63) | 8 | 75.45 (19.69) | 69.67 (22.18) | 57.66 (9.12) | 0.55 | 0.06 | 0.23 |
| PRPV (m/s) | 3 | 2.70 (0.20) | 4 | 3.09 (0.33) | 2.34 (0.47) | 3.15 (0.58) | 0.10 | 0.32 | 0.17 |
| AT:ET | 4 | 0.21 (0.04) | 6 | 0.29 (0.12) | 0.22 (0.06) | 0.27 (0.08) | 0.26 | 0.54 | 0.31 |
| RPAD(%) | 3 | 8.37 (1.66) | 3 | 15.21 (2.72) | 16.40 (7.45) | 23.33 (2.69) | 0.02 | 0.053 | 0.98 |
A: comparison of variable means for treatment regardless of time; B: comparison of variable means for time regardless of treatment; C: interaction between treatment and time; AT:ET: acceleration time (AT) indexed to the ejection time (ET) of pulmonary artery flow; time PRPV: pulmonary regurgitation peak velocity; RPAD: right pulmonary artery dispensability index; PRPV: pulmonary regurgitation peak velocity; m: meter; mmHg: millimeter of mercury; mm: millimeter; n: number; sPAP: systolic pulmonary arterial pressure; s: second; TRFV: tricuspid regurgitant flow velocity.